Medicine is on the verge of a tremendous leap in the personalization of care. The decoding of the human genome has opened up an entirely new science for diagnosis and treatment of disease. Advances in material science, information technology, and nanotechnology are allowing for the development of inexpensive and finely tuned diagnostic testing that provides clinicians with patient-specific information that was never available previously. Unlike diagnostic tests that are performed on millions of patients, many of these new tests are targeted at only thousands of patients.
Personalized medicine utilizes specific genetic patient information to determine which of the various disease treatment options is most likely to deliver the best outcome. Researchers learn what works best through their analysis of large patient experiential databases, knowledge of cellular biology, and understanding of pharmacokinetics.
Currently, patients are treated according to what works best for the majority of patients with a particular disease. There is only rudimentary customization of care and little information or justification for it to be truly personalized. Medical experts just do not know enough about what works better in which patients. This is all about to change.
In the near future, a patient with diabetes and a family history of coronary artery disease will be able to use a genetic diagnostic test to determine what treatment regimen specifically, drugs in what combination and dose (e.g., insulin, cholesterol-lowering medications, etc.) is most likely to deliver the greatest glucose control, lowest cholesterol levels, and highest quality of life. Today, physicians utilize only gross guidelines and trial and error to determine what might be best for each patient.
Although this promising area of medicine seems to offer a very bright future, it is not free of challenges. Today, clinicians struggle mightily to keep up with all the newly released medical knowledge. In addition, medicine tends to integrate new discoveries very slowly into mainstream practice.
Personalized medicine with all of its new permutations of results and treatments is surely poised to overwhelm even the most accomplished practitioner. In fact, some biotech companies worry more about getting clinicians to use their new tests than they do about their ability to develop them. These biotech companies understand the huge task ahead to educate clinicians in the value of their tests, and more importantly, how their findings should be used in different patients. These companies fear that physicians will be overwhelmed by the complexity of these tests and not be able to take advantage of the potential results they deliver. They believe some physicians will shun the tests altogether because many have been taught that a test should never be ordered unless the results will be used.
Problem for Physicians
The personalization of medicine really does present a big problem for the physician. It is impossible to effectively use these tests without the help of some type of information technology system that analyzes the results of the test, the characteristics of the patient, and offers the physician recommendations for treatment that can be discussed with each patient.
The introduction of clinical decision-support tools embedded within computerized physician order entry systems are one possible way to integrate the personalized medicine clinical knowledge into a clinical information system that can be utilized by physicians. Unfortunately, these systems are being slowly adopted by organizations and clinicians. Nevertheless, some form of easy to use, workflow friendly, clinical decision support is needed before personalized medicine will become widespread.
Over the next decade, personalized medicine will be heavily marketed to patients and their clinicians. It offers tremendous benefits through its fine tuning of treatment protocols to deliver the best outcomes with the least morbidity. Its advent only makes the deployment of clinical decision support more urgent, and it might possibly be a major force in getting clinical information technology more widely deployed and utilized through all levels of care.
Barry P. Chaiken (email@example.com) has more than 20 years of experience in medical research, epidemiology, clinical information technology, and patient safety. As founder of his own company, he has worked on quality improvement studies and clinical investigations for the National Institutes of Health, Framingham Heart Study, and Boston University Medical School. Chaiken is board certified in general preventive medicine and public health and is a Fellow of HIMSS. He is the associate chief medical officer of BearingPoint, Inc., and serves on the Editorial Advisory Board for Patient Safety and Quality Healthcare.